ArticleNature2026
GLP-1R-GIPR-PPARα/γ/δ quintuple agonism corrects obesity and diabetes in mice.
Erratum issuedAbstract read
In one paragraph
Article in Nature, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Review
- One drug, five targets.Cell research · 2026Article
- From dual to quintuple agonism for next-generation pharmacology to treat obesity and type 2 diabetes: synergistic incretin and nuclear receptor signaling.Cardiovascular diabetology. Endocrinology reports · 2026Article
- An updated overview of alkaloids for the prevention and treatment of metabolic dysfunction-associated steatotic liver disease.Frontiers in pharmacology · 2026Review
Corrections and comments
- Erratum issued
Authors and funding
53 authors.
Daniela Liskiewicz *Institute for Diabetes and Obesity, Helmholtz, Munich, Germany.ORCID http://orcid.org/0000-0002-5859-6316
Aaron Novikoff *Institute for Diabetes and Obesity, Helmholtz, Munich, Germany.
Ahmed KhalilInstitute for Diabetes and Obesity, Helmholtz, Munich, Germany.ORCID http://orcid.org/0009-0000-2204-8636
Seun AkindehinInstitute for Diabetes and Obesity, Helmholtz, Munich, Germany.
Jonathan E CampbellDepartment of Pharmacology and Cancer Biology, Duke University, Durham, NC, USA.ORCID http://orcid.org/0000-0003-4358-6331
Pietra CandelaUR 2465, Laboratoire de la Barrière Hémato-Encéphalique (LBHE), Université Artois, Lens, France.
Russell L CastelinoInstitute for Diabetes and Obesity, Helmholtz, Munich, Germany.ORCID http://orcid.org/0009-0008-7446-6299
Callum CouplandInstitute for Diabetes and Obesity, Helmholtz, Munich, Germany.
Maxime CulotUR 2465, Laboratoire de la Barrière Hémato-Encéphalique (LBHE), Université Artois, Lens, France.ORCID http://orcid.org/0000-0001-7452-0867
W Scott DodsonIndiana Biosciences Research Institute, Indianapolis, IN, USA.
Jonathan D DourosIndiana Biosciences Research Institute, Indianapolis, IN, USA.
Hannes EmbringNovo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Annette FeuchtingerCore Facility Pathology and Tissue Analytics, Helmholtz, Munich, Germany.
Brian FinanNovo Nordisk Research Center Indianapolis, Indianapolis, IN, USA.ORCID http://orcid.org/0000-0003-1178-8481
Cristina Garcia-CaceresInstitute for Diabetes and Obesity, Helmholtz, Munich, Germany.
Xiao-Bing GaoDepartment of Comparative Medicine, Yale University School of Medicine, New Haven, CT, USA.ORCID http://orcid.org/0000-0002-2035-4936
Fabien GosseletUR 2465, Laboratoire de la Barrière Hémato-Encéphalique (LBHE), Université Artois, Lens, France.ORCID http://orcid.org/0000-0002-0481-5026
Gerald GrandlInstitute for Diabetes and Obesity, Helmholtz, Munich, Germany.ORCID http://orcid.org/0000-0003-4456-1988
Robert M GutgesellInstitute for Diabetes and Obesity, Helmholtz, Munich, Germany.ORCID http://orcid.org/0000-0001-6137-0468
Daniel T HaasInstitute for Diabetes and Obesity, Helmholtz, Munich, Germany.
Martin JastrochDepartment of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University, Stockholm, Sweden.ORCID http://orcid.org/0000-0003-0358-3865
Ezgi KaraogluInstitute for Diabetes and Obesity, Helmholtz, Munich, Germany.ORCID http://orcid.org/0009-0003-2639-6015
Pamela KakimotoInstitute for Diabetes and Obesity, Helmholtz, Munich, Germany.
Anna Cristina KaltenbachInstitute for Cardiovascular Prevention (IPEK), University Hospital, LMU Munich, Munich, Germany.ORCID http://orcid.org/0009-0006-3196-5288
Michaela KeuperDepartment of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University, Stockholm, Sweden.ORCID http://orcid.org/0000-0003-0319-3509
Christine M KusminskiTouchstone Diabetes Center, The University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID http://orcid.org/0000-0002-3671-0341
Danielle C LeanderDuke Molecular Physiology Institute, Department of Medicine, Division of Endocrinology, Duke University, Durham, NC, USA.ORCID http://orcid.org/0009-0000-7507-001X
Arkadiusz LiskiewiczInstitute for Diabetes and Obesity, Helmholtz, Munich, Germany.ORCID http://orcid.org/0000-0002-4102-5373
Xue LiuInstitute for Diabetes and Obesity, Helmholtz, Munich, Germany.
Gandhari Maity-KumarInstitute for Diabetes and Obesity, Helmholtz, Munich, Germany.
Sara Martinez MartinezCIMUS, University of Santiago de Compostela, Instituto de Investigación Sanitaria, Santiago de Compostela, Spain.ORCID http://orcid.org/0000-0002-7258-9083
Stephanie A MoweryIndiana Biosciences Research Institute, Indianapolis, IN, USA.
Ruben NogueirasCIMUS, University of Santiago de Compostela, Instituto de Investigación Sanitaria, Santiago de Compostela, Spain.ORCID http://orcid.org/0000-0002-9976-9930
Marshall PaisleyDuke Molecular Physiology Institute, Department of Medicine, Division of Endocrinology, Duke University, Durham, NC, USA.
Diego Perez-TilveDepartment of Pharmacology and Systems Physiology, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Patricia S S PetersenNovo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.ORCID http://orcid.org/0000-0003-2560-1446
Paul T PflugerInstitute for Diabetes and Obesity, Helmholtz, Munich, Germany.
Sneha PrakashInstitute for Diabetes and Obesity, Helmholtz, Munich, Germany.
Sabine SteffensInstitute for Cardiovascular Prevention (IPEK), University Hospital, LMU Munich, Munich, Germany.ORCID http://orcid.org/0000-0002-6892-9751
Alberto Cebrian-SerranoInstitute for Diabetes and Obesity, Helmholtz, Munich, Germany.ORCID http://orcid.org/0000-0002-4737-0215
Monica TostCore Facility Pathology and Tissue Analytics, Helmholtz, Munich, Germany.
Jordan WeanDepartment of Surgery, University of Michigan, Ann Arbor, MI, USA.ORCID http://orcid.org/0000-0002-9459-0093
Christian WeberInstitute for Cardiovascular Prevention (IPEK), University Hospital, LMU Munich, Munich, Germany.
Junichi YoshidaDepartment of Comparative Medicine, Yale University School of Medicine, New Haven, CT, USA.ORCID http://orcid.org/0000-0003-4175-4258
Zachary Gerhart-HinesNovo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.ORCID http://orcid.org/0000-0003-2981-4991
Tamas L HorvathDepartment of Comparative Medicine, Yale University School of Medicine, New Haven, CT, USA.ORCID http://orcid.org/0000-0002-7522-4602
Philipp E SchererTouchstone Diabetes Center, The University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID http://orcid.org/0000-0003-0680-3392
Randy J SeeleyDepartment of Surgery, University of Michigan, Ann Arbor, MI, USA.ORCID http://orcid.org/0000-0002-3721-5625
Richard D DiMarchiDepartment of Chemistry, Indiana University, Bloomington, IN, USA.ORCID http://orcid.org/0000-0003-0220-4085
Matthias H TschöpHelmholtz Munich, Munich, Germany.
Natalie KrahmerInstitute for Diabetes and Obesity, Helmholtz, Munich, Germany.
Patrick J KnerrIndiana Biosciences Research Institute, Indianapolis, IN, USA.
Timo D MüllerInstitute for Diabetes and Obesity, Helmholtz, Munich, Germany. timodirk.mueller@helmholtz-munich.de.ORCID http://orcid.org/0000-0002-0624-9339
Funding
Regional Pilot And Feasibility Study Grants ProgramP30DK020572 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Mehboob A Hussain · 2013 to 2026
$24.3MIntestinal Reg3g as a mediator of dietary, pharmacological and surgical therapies for obesity and diabetesR01DK133140 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SEELEY, RANDY J · 2022 to 2025
$2.1MNIDDK NIH HHS P30 DK020572NIDDK NIH HHS R01 DK133140
Abstract
There are increasing numbers of effective drugs to improve obesity-linked metabolic dysfunction; GLP-1R-GIPR co-agonism is effective in the management of obesity and type 2 diabetes
Indexed as
Diabetes Mellitus, Type 2Glucagon-Like Peptide-1 Receptor AgonistsObesityPPAR alphaPPAR deltaPPAR gammaAnimalsBlood GlucoseBody WeightButyratesFemaleGlucagon-Like Peptide 1Glucagon-Like Peptide-1 ReceptorHumansInsulinInsulin ResistanceBlood GlucoseButyratesgastric inhibitory polypeptide receptorGlp1r protein, mouseGlucagon-Like Peptide 1Glucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor AgonistsInsulinPPAR alphaPPAR deltaPPAR gammaReceptors, Gastrointestinal Hormone
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.